Promoters' Encumbrance Released: Docon Technologies Releases Pledge on 1.75 Crore Shares of Thyrocare Technologies Limited
Docon Technologies Private Limited, a promoter of Thyrocare Technologies Limited, has announced the release of a pledge concerning 1,75,00,000 equity shares of the company. This transaction occurred on August 11, 2026, involving the Debenture Trustee, Catalyst Trusteeship Limited.The pledge was created against Docon's substantial stake in Thyrocare Technologies Limited. As per disclosures made by Docon Technologies Private Limited, the company holds a total of 9,69,69,696 equity shares in Thyrocare, representing 60.92% of the equity share capital as of August 11, 2026.
The release of the pledge pertains to a portion of Docon's holdings that had been used as security for Non-Convertible Debentures (NCDs) issued by API Holdings Limited, the holding company of Docon.
Shareholding and Encumbrance Details
Prior to the pledge release, the total shares held by Docon were encumbered. The details concerning the shareholding and encumbered shares are summarized below:| Category | Shares Carrying Voting Rights (A) | Shares in Nature of Encumbrance (B) | Total Holding (A+B) | % of Diluted Share Capital |
|---|---|---|---|---|
| Before Pledge Release | NIL | 9,69,69,696 | 9,69,69,696 | 60.92% |
| After Pledge Release | 1,75,00,000 | 7,94,69,696 | 9,69,69,696 | 60.92% |
Following the release of the pledge over 1,75,00,000 equity shares on August 11, 2026, Docon's total shareholding in Thyrocare remains unchanged at 9,69,69,696 equity shares. The number of encumbered shares was reduced from 9,69,69,696 to 7,94,69,696.
Details of Underlying Debentures
The pledged shares were connected to the Non-Convertible Debentures (NCDs) issued by API Holdings Limited and held in favour of Catalyst Trusteeship Limited. The current outstanding principal amount of these NCDs is INR 10,500 million.Details regarding the NCDs include:
| S. No. | Name of NCD Holder | Amount (INR in Mn) |
|---|---|---|
| 1 | Poonawalla Fincorp Limited | 918.75 |
| 2 | 360 One Income Opportunities Fund - Series 7 | 131.25 |
| 3 | Bagla Industries Private Limited | 21.00 |
| 4 | Tata Capital Limited | 2,843.75 |
| 5 | Ganesh Polychem Ltd | 43.75 |
| 6 | 360 One Prime Limited | 4,870.25 |
| 7 | Advik Hi Tech Private Limited | 29.75 |
| 8 | Micro Labs Limited | 59.50 |
| 9 | Sak Industries Private Ltd | 151.38 |
| 10 | Ban Labs Private Limited | 55.13 |
| 11 | Lake Chemicals P Ltd | 29.75 |
| 12 | Sonnet Trade and Investments Pvt Ltd | 9.63 |
| 13 | Vara Future LLP | 29.75 |
| 14 | Moorjani Ventures Private Limited | 29.75 |
| 15 | Medley Pharmaceuticals Limited | 29.75 |
| 16 | Bennett Coleman and Company Limited | 437.50 |
| 17 | Urmila Behera | 12.25 |
| 18 | Warmond Fiduciary Services Limited | 12.25 |
| 19 | Warmond Fiduciary Services Limited | 22.75 |
| 20 | Warmond Fiduciary Services Limited | 22.75 |
| 21 | Warmond Fiduciary Services Limited | 5.25 |
| 22 | Mvs Ventures Private Limited | 58.62 |
| 23 | Alkram Venture Private Limited | 58.62 |
| 24 | Warmond Fiduciary Services Limited | 17.50 |
| 25 | Warmond Fiduciary Services Limited | 35.00 |
| 26 | Warmond Fiduciary Services Limited | 17.50 |
| 27 | Warmond Fiduciary Services Limited | 12.25 |
| 28 | Rajendrakumar Shivkishan Agrawal | 87.50 |
| 29 | Harjeet Kohli | 26.25 |
| 30 | Pitre Business Ventures LLP | 29.75 |
| 31 | Dayanidhi Maran | 59.50 |
| 32 | JPM Merchandise Agencies Limited | 17.50 |
| 33 | J Kumar Infra projects Limited | 314.12 |
THYROCARE Stock Price Movement
As of 11:55 AM in live trading, shares of Thyrocare Technologies Limited are shedding value by 4.50%, currently hovering at ₹614.00 as they trade against their recent high-level valuation. The stock has seen significant intraday movement, with over 4.12 million shares traded during the session so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: